Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | DUT | P33316 | 8/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17295676 | 0.84 | PKM (0.43) | PKMALDH1A1LMNADUTCRBN | |
| SCHEMBL4278691 | 0.81 | PKM (0.38) | PKMALDH1A1LMNADUTCRBN | |
| SCHEMBL7198476 | 0.81 | — | — | |
| SCHEMBL20529215 | 0.76 | ALDH1A1 (0.44) | PKMALDH1A1LMNADUTCRBN | |
| SCHEMBL744415 | 0.76 | IDH1 (0.42) | PKMALDH1A1DUT | |
| SCHEMBL8656960 | 0.75 | PKM (0.45) | PKMALDH1A1LMNADUTCRBN | |
| SCHEMBL6425133 | 0.75 | L3MBTL1 (0.43) | PKMALDH1A1DUTCRBNL3MBTL1 | |
| SCHEMBL5792152 | 0.73 | CRBN (0.42) | PKMALDH1A1LMNADUTCRBN | |
| SCHEMBL41240 | 0.73 | PKM (0.42) | PKMDUTCRBNL3MBTL1 | |
| SCHEMBL7213480 | 0.72 | PKM (0.46) | PKMDUTCRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230148152-A1 | METHOD OF SYNTHESIZING SINGLE-STRANDED NUCLEOTIDE SEQUENCE, BLOCKED NUCLEOSIDE TRIPHOSPHATES AND RELATED METHODS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-05-11 | — | — | US | claimed |
| US-20170159044-A1 | COMPOSITIONS AND METHODS FOR SYNTHETIC GENE ASSEMBLY | Twist Bioscience Corporation | 2017-06-08 | — | — | US | claimed |
| US-20170015667-A1 | THIOL-X CLICK FOLDAMERS FOR POLYMER AFFINITY AND CATALYSIS LIBRARIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-01-19 | — | — | US | claimed |
| EP-3692152-B1 | METHODS AND COMPOSITIONS FOR ALTERING FUNCTION AND STRUCTURE OF CHROMATIN LOOPS AND/OR DOMAINS | BROAD INST INC (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025128693-A1 | AN ENGINEERED MAMMALIAN NUCLEASE FOR IMPROVED MAPPING OF 3-D GENOME ARCHITECTURE FROM NUCLEOSOME TO CHROMOSOME SCALE | THE ROCKEFELLER UNIVERSITY (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250163498-A1 | METHODS AND COMPOSITIONS RELATED TO NUCLEIC ACID-BASED FLUORESCENT NANOCLUSTER PROBES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-05-22 | — | — | US | disclosed |
| WO-2025081111-A1 | METHODS AND COMPOSITIONS FOR CHARACTERIZING RNA-BINDING PROTEIN BINDING SITES BY IN-SITU REVERSE TRANSCRIPTION-BASED SEQUENCING | THE UNIVERSITY OF CHICAGO (US) | 2025-04-17 | — | — | WO | disclosed |
| EP-4514962-A1 | PROFILING RNA AT CHROMATIN TARGETS IN SITU BY ANTIBODY-TARGETED TAGMENTATION | Fred Hutchinson Cancer Center (US) | 2025-03-05 | — | — | EP | disclosed |
| WO-2025038951-A1 | METHODS AND COMPOSITIONS FOR INTEGRATION OF RNA INTO A DNA GENOME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-02-20 | — | — | WO | disclosed |
| WO-2025024577-A1 | INCORPORATING UNNATURAL AMINO ACIDS USING ONE POT PURE SYSTEM | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-01-30 | — | — | WO | disclosed |
| US-12188099-B2 | Integrated proviral sequencing assay | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-01-07 | — | — | US | disclosed |
| US-20030170675-A1 | Methods of manipulating nucleic acids | THE GOV'T OF THE U.S OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERV. | 2003-09-11 | — | — | US | disclosed |
| US-20030059919-A1 | Novel human 39228, 21956, 25856, 22244, 8701, 32263, 50250, 55158, 47765, 62088, 50566, and 48118 molecules and uses therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-03-27 | — | — | US | disclosed |
| EP-1282696-A1 | IFI206, A NOVEL INTERFERON-INDUCED POLYPEPTIDE, AND NUCLEIC ACIDS ENCODING THE SAME | Curagen Corporation (US) | 2003-02-12 | — | — | EP | disclosed |
| EP-1246636-A2 | MOLECULES THAT INFLUENCE PATHOGEN RESISTANCE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001068830-A1 | IFI206, A NOVEL INTERFERON-INDUCED POLYPEPTIDE, AND NUCLEIC ACIDS ENCODING THE SAME | CURAGEN CORPORATION (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001049835-A2 | MOLECULES THAT INFLUENCE PATHOGEN RESISTANCE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-07-12 | — | — | WO | disclosed |
| WO-2001023568-A2 | MEMBERS OF THE IAP GENE FAMILY | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH (US) | 2001-04-05 | — | — | WO | disclosed |
| WO-1998046756-A9 | SECRETED PROTEIN SSP-1 COMPOSITIONS AND THERAPEUTIC AND DIAGNOSTIC USES THEREFOR | — | 1999-03-11 | — | — | WO | disclosed |
| WO-1998046756-A1 | SECRETED PROTEIN SSP-1 COMPOSITIONS AND THERAPEUTIC AND DIAGNOSTIC USES THEREFOR | MILLENNIUM BIOTHERAPEUTICS (US) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015667-A1 | THIOL-X CLICK FOLDAMERS FOR POLYMER AFFINITY AND CATALYSIS LIBRARIES | TST, FES, STS | PKM 1129/4885ALDH1A1 3787/4885LMNA 4424/4885 |
| US-20230148152-A1 | METHOD OF SYNTHESIZING SINGLE-STRANDED NUCLEOTIDE SEQUENCE, BLOCKED NUCLEOSIDE TRIPHOSPHATES AND RELATED METHODS | RNGTT, NT5C3B, TYMP | PKM 3312/4885ALDH1A1 3602/4885LMNA 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.